Real-time Estimate
Cboe BZX
14:30:04 06/05/2024 BST
|
5-day change
|
1st Jan Change
|
47.22
USD
|
+0.03%
|
|
+12.06%
|
+32.66%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
607.7
|
464.5
|
1,340
|
984.7
|
2,377
|
3,717
|
-
|
-
|
Enterprise Value (EV)
1 |
489.3
|
293.7
|
1,006
|
650.3
|
1,818
|
3,194
|
3,260
|
3,474
|
P/E ratio
|
-12
x
|
-5.83
x
|
-10.1
x
|
-5.81
x
|
-9.64
x
|
-14.4
x
|
-13.2
x
|
-13.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
509
x
|
6,543
x
|
1,243
x
|
208
x
|
592
x
|
2,177
x
|
141
x
|
42.4
x
|
EV / Revenue
|
410
x
|
4,136
x
|
933
x
|
137
x
|
453
x
|
1,871
x
|
124
x
|
39.6
x
|
EV / EBITDA
|
-9.24
x
|
-3.97
x
|
-9.42
x
|
-3.9
x
|
-8.21
x
|
-12.1
x
|
-12.1
x
|
-12.4
x
|
EV / FCF
|
-10.4
x
|
-4.72
x
|
-11.3
x
|
-5.56
x
|
-10.6
x
|
-15.2
x
|
-15.2
x
|
-13.8
x
|
FCF Yield
|
-9.58%
|
-21.2%
|
-8.85%
|
-18%
|
-9.4%
|
-6.56%
|
-6.56%
|
-7.25%
|
Price to Book
|
5.18
x
|
2.54
x
|
3.29
x
|
3.12
x
|
4.5
x
|
5.6
x
|
6.28
x
|
7.57
x
|
Nbr of stocks (in thousands)
|
24,222
|
32,922
|
47,157
|
53,810
|
66,799
|
78,744
|
-
|
-
|
Reference price
2 |
25.09
|
14.11
|
28.41
|
18.30
|
35.58
|
47.20
|
47.20
|
47.20
|
Announcement Date
|
09/03/20
|
30/03/21
|
30/03/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.193
|
0.071
|
1.078
|
4.737
|
4.013
|
1.707
|
26.33
|
87.62
|
EBITDA
1 |
-52.94
|
-74
|
-106.8
|
-166.9
|
-221.5
|
-263.3
|
-269.1
|
-279.3
|
EBIT
1 |
-53.83
|
-74.95
|
-107.7
|
-167.9
|
-222.6
|
-259.3
|
-275.3
|
-274.8
|
Operating Margin
|
-4,512.32%
|
-105,567.61%
|
-9,990.91%
|
-3,544.06%
|
-5,547.17%
|
-15,186.18%
|
-1,045.68%
|
-313.66%
|
Earnings before Tax (EBT)
1 |
-50.42
|
-73.81
|
-107.6
|
-163.9
|
-209.3
|
-240.8
|
-257.3
|
-242.3
|
Net income
1 |
-50.42
|
-73.81
|
-107.6
|
-163.9
|
-214.5
|
-242.6
|
-270
|
-275.9
|
Net margin
|
-4,226.49%
|
-103,960.56%
|
-9,985.25%
|
-3,460.38%
|
-5,345.85%
|
-14,209.19%
|
-1,025.75%
|
-314.87%
|
EPS
2 |
-2.090
|
-2.420
|
-2.800
|
-3.150
|
-3.690
|
-3.277
|
-3.570
|
-3.506
|
Free Cash Flow
1 |
-46.87
|
-62.21
|
-89.02
|
-116.9
|
-171
|
-209.5
|
-214
|
-252
|
FCF margin
|
-3,929%
|
-87,623.94%
|
-8,258.26%
|
-2,466.98%
|
-4,261.03%
|
-12,270.62%
|
-812.91%
|
-287.6%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/03/20
|
30/03/21
|
30/03/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
1.078
|
3.131
|
0.439
|
0.458
|
0.709
|
2.679
|
0.988
|
0.346
|
-
|
0.1818
|
0.6364
|
0.1818
|
0.6364
|
0.0332
|
EBITDA
1 |
-27.57
|
-30.65
|
-33.59
|
-42.83
|
-43.21
|
-47.28
|
-47.7
|
-
|
-
|
-62.4
|
-60.07
|
-62.68
|
-65.77
|
-69.39
|
-
|
EBIT
1 |
-27.81
|
-30.89
|
-33.83
|
-43.04
|
-43.45
|
-47.56
|
-47.98
|
-53
|
-58.98
|
-62.66
|
-62.44
|
-64.55
|
-66.96
|
-68.97
|
-68.13
|
Operating Margin
|
-
|
-2,865.31%
|
-1,080.39%
|
-9,805.24%
|
-9,487.77%
|
-6,707.48%
|
-1,790.89%
|
-5,363.87%
|
-17,045.38%
|
-
|
-34,341.54%
|
-10,143.56%
|
-36,829.97%
|
-10,838.51%
|
-204,914.29%
|
Earnings before Tax (EBT)
1 |
-27.85
|
-30.79
|
-34.63
|
-42.38
|
-41.92
|
-44.99
|
-46
|
-50.98
|
-57.46
|
-55.9
|
-57.82
|
-59.96
|
-62.51
|
-64.56
|
-65.01
|
Net income
1 |
-27.85
|
-30.79
|
-34.63
|
-42.38
|
-41.92
|
-44.99
|
-46
|
-50.98
|
-57.46
|
-60.1
|
-58.97
|
-60.37
|
-62.73
|
-64.75
|
-65.01
|
Net margin
|
-
|
-2,856.59%
|
-1,105.94%
|
-9,652.62%
|
-9,153.93%
|
-6,345.7%
|
-1,716.87%
|
-5,159.82%
|
-16,606.36%
|
-
|
-32,431.79%
|
-9,487.08%
|
-34,503.81%
|
-10,175.7%
|
-195,529.83%
|
EPS
2 |
-0.7300
|
-0.6800
|
-0.7300
|
-0.8100
|
-0.7800
|
-0.8400
|
-0.8500
|
-0.9400
|
-1.010
|
-0.9000
|
-0.8030
|
-0.7918
|
-0.8319
|
-0.8476
|
-0.9075
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
05/11/21
|
30/03/22
|
12/05/22
|
12/08/22
|
14/11/22
|
28/02/23
|
04/05/23
|
08/08/23
|
07/11/23
|
28/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
118
|
171
|
334
|
334
|
559
|
523
|
457
|
243
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-46.9
|
-62.2
|
-89
|
-117
|
-171
|
-210
|
-214
|
-252
|
ROE (net income / shareholders' equity)
|
-36.4%
|
-51.6%
|
-43%
|
-50.6%
|
-50.2%
|
-43.7%
|
-42.1%
|
-47.5%
|
ROA (Net income/ Total Assets)
|
-33.4%
|
-47%
|
-40.3%
|
-46.6%
|
-43.4%
|
-39.3%
|
-35.4%
|
-40.8%
|
Assets
1 |
150.9
|
156.9
|
267.2
|
351.6
|
493.8
|
616.9
|
762.3
|
676.3
|
Book Value Per Share
2 |
4.850
|
5.550
|
8.640
|
5.870
|
7.910
|
8.430
|
7.510
|
6.230
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.49
|
0.19
|
0.44
|
1.66
|
4.69
|
1
|
7.5
|
14
|
Capex / Sales
|
41.24%
|
261.97%
|
40.45%
|
34.96%
|
116.82%
|
58.57%
|
28.49%
|
15.98%
|
Announcement Date
|
09/03/20
|
30/03/21
|
30/03/22
|
28/02/23
|
28/02/24
|
-
|
-
|
-
|
Last Close Price
47.2
USD Average target price
56.86
USD Spread / Average Target +20.46% Consensus |
1st Jan change
|
Capi.
|
---|
| +32.66% | 3.72B | | +25.69% | 47.9B | | +47.30% | 41.42B | | -3.46% | 40.7B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|